Eufula Dialysis, Llc is a medicare approved dialysis facility center in Paterson, New Jersey and it has 18 dialysis stations. It is located in Passaic county at 680 Broadway, Paterson, NJ, 07514. You can reach out to the office of Eufula Dialysis, Llc at (973) 357-8079. This dialysis clinic is managed and/or owned by Davita. Eufula Dialysis, Llc has the following ownership type - Profit. It was first certified by medicare in October, 2014. The medicare id for this facility is 312643 and it accepts patients under medicare ESRD program.
| Name | Eufula Dialysis, Llc |
|---|---|
| Location | 680 Broadway, Paterson, New Jersey |
| No. of Dialysis Stations | 18 |
| Medicare ID | 312643 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 680 Broadway, Paterson, New Jersey, 07514 | |
| (973) 357-8079 | |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
| NPI Number | 1174954234 |
| Organization Name | East Paterson Dialysis |
| Doing Business As | Eufaula Dialysis Llc |
| Address | 680 Broadway Paterson, New Jersey, 07514 |
| Phone Number | (615) 320-4414 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 36 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 14 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 60 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 536 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Eufula Dialysis, Llc with elevated calcium levels.
| Patients with hypercalcemia | 60 |
| Hypercalcemia patient months | 539 |
| Patients with Serumphosphor | 66 |
| Patients with Serumphosphor less than 3.5 mg/dL | 13 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 32 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 16 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 53 |
| Patient months included in arterial venous fistula and catheter summaries | 403 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 88 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 63 |
| Hospitalization Rate in facility | 243.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 380 |
| Hospitalization Rate: Lower Confidence Limit | 160.7 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Eufula Dialysis, Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 23.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 32 |
| Readmission Rate: Lower Confidence Limit | 16.6 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Eufula Dialysis, Llc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .23 (As Expected) |
| SIR: Upper Confidence Limit | 1.12 |
| SIR: Lower Confidence Limit | .01 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Eufula Dialysis, Llc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 50 |
| Transfusion Rate in facility | 43.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 112.4 |
| Transfusion Rate: Lower Confidence Limit | 19.1 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Eufula Dialysis, Llc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 117 |
| Mortality Rate in facility | 16.3 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 29.2 |
| Mortality Rate: Lower Confidence Limit | 8.2 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago
ST. Joseph's Sjrmc Dialysis Location: 703 Main Street, Paterson, New Jersey, 07503 Phone: (973) 754-3570 |
ST. Joseph's Paterson Dialysis Location: 11 Getty Avenue, Paterson, New Jersey, 07503 Phone: (973) 684-3490 |
ARA Great Falls Dialysis, Llc Location: 498 East 30th Street, Paterson, New Jersey, 07504 Phone: (973) 569-0500 |
News Archive
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.
University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.
› Verified 2 days ago